An interventional study of Short withdrawal of testosterone, gonadotropins or estrogenic compounds (see below) in Kallmann Syndrome, sponsored by Hospital for Children and Adolescents, Finland. Enrolling by invitation at 1 site in Finland. Open to participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-02-25.
Sponsored by Hospital for Children and Adolescents, Finland · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Objective is to characterize epidemiology, clinical and genetic features of Kallmann syndrome in Finland.
Kallmann syndrome is comprised of idiopathic hypogonadotropic hypogonadism and anosmia (inability to smell). Associated phenotypes may include cryptorchidism, microphallus, bone deformations, mirror movements, hearing loss and infertility. Objective is to characterize epidemiology, clinical and genetic features of Kallmann syndrome in Finland.
23 studies on the registry are indexed under Kallmann Syndrome; 5 are open to participants now.
This study's planned enrollment of 50 is below the median of 75 across 14 interventional studies indexed under Kallmann Syndrome.
Browse Kallmann Syndrome studies →Hospital for Children and Adolescents, Finland is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
clinical examination, biochemical profile, and genetic characterization. Possibility to stop hormone therapy with drugs containing testosterone (Atmos®, Testim®, Testogel®, Nebido®, Panteston®, Sustanon®), FSH (Gonal-F®, Puregon®), hCG (Pregnyl®), estrogenic compounds (such as Estrofem®, Divigel®, Estrena®, Climara®, Estradot®, Evorel®, Femseven®: Merimono®, Progynova®, Ovestin®, Zumenon®, Estrogel®, Femoston®, Femoston combi®, Divina®, Divitren®, Indivina®, Estalis sekvens®, Evorel sequi®, Novofem®, Trisekvens®, Activelle®, Estalis®, Evorel conti®, Kliogest®, Mericomb®, Mericomb Mite®, Merigest®: Angeliq®) for 3 mo to assess reversibility of GnRH-deficiency will be offered.
Clinical features including quality of life, reversibility and genetic features of Kallmann syndrome in Finland
Time frame: 0, 3 mo and during subsequent F/U
epidemiology
Time frame: by 2012 (anticipated)
The record gives a start of Dec 2007, a primary completion of Dec 2012 and a completion of Dec 2025. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital for Children and Adolescents, Finland